Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Clinical trial NCT02492737 · COMPLETED

Trial details

NCT number: NCT02492737
Sponsor: Agios Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome Hematologic Malignancies

Start date: 2015-08-07
Primary completion: 2018-03-21
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.